When Kedrion Biopharma was presented with the opportunity to commercialize YIMMUGO in the United States, the company moved swiftly. The decision reflected a clear commitment to expanding access to immunoglobulin therapies and supporting patients with timely, reliable treatment options.
Once the marketing strategy was in place, attention turned to distribution—a critical piece of the launch puzzle. After extensive internal collaboration, Kedrion opted for a limited distribution model, designed to streamline logistics and ensure consistent access for patients and providers.
“When we decided to select a single distributor, CuraScript SD’s demonstrated expertise in the Ig market and consistent reliability made them the ideal choice to serve the specialty pharmacy members of Kedrion’s limited distribution network and other customers.” said Lynda Bowe, VP of Corporate Accounts, Hospital & Inside Sales at Kedrion Biopharma.
The partnership goes beyond logistics. Kedrion and CuraScript SD are working closely with a network of specialty pharmacies to ensure coast-to-coast availability of YIMMUGO. The goal is not just to launch a product, but to build a sustainable model for growth and patient support.
“We’re proud to partner with Kedrion Biopharma and be the exclusive distributor for YIMMUGO,” said Jeremy Schmucker, Vice President Sales & Marketing at CuraScript SD. “Our deep relationships with specialty pharmacies, clinicians, and healthcare providers position us to deliver YIMMUGO with impact and precision.” Mr. Schumucker went on to add, “With a strong commitment to partnership that supports every phase of the process, we prioritize efficient operations and compassionate patient care.”
As the rollout continues, both companies remain focused on operational excellence and compassionate care—two pillars they believe are essential to delivering meaningful impact in the immunoglobulin space.
“This exclusivity allows us to fully align our commercial strategy with the vision of the manufacturer of YIMMUGO, Biotest AG, ensuring a seamless launch and sustained market growth.” said Bob Rossilli, Chief Commercial Officer at Kedrion Biopharma.